Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 3—March 2024
Dispatch

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia

Gunar GüntherComments to Author , Lusia Mhuulu, Azaria Diergaardt, Viola Dreyer, Maria Moses, Kaarna Anyolo, Nunurai Ruswa, Mareli Claassens, Stefan Niemann1, and Emmanuel Nepolo1
Author affiliations: Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland (G. Günther); University of Namibia, Windhoek, Namibia (G. Günther, L. Mhuulu, A. Diergaardt, M. Claassens, S. Niemann, E. Nepolo); Katutura State Hospital, Windhoek, Namibia (G. Günther, M. Moses, K. Anyolo); Research Center Borstel, Borstel, Germany (V. Dreyer, S. Niemann); German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel (V. Dreyer, S. Niemann); National Tuberculosis and Leprosy Programme, Windhoek, Namibia (N. Ruswa)

Main Article

Figure 1

Chest radiographs showing lungs of patient in Namibia who developed bedaquiline resistance. A) At treatment initiation; B) at culture conversion; C) 3 months after conversion.

Figure 1. Chest radiographs showing lungs of patient in Namibia who developed bedaquiline resistance. A) At treatment initiation; B) at culture conversion; C) 3 months after conversion.

Main Article

1These authors contributed equally to this article.

Page created: February 08, 2024
Page updated: February 22, 2024
Page reviewed: February 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external